A NAD⁺ patch is an adhesive square you wear for eight to fourteen hours, sold for anywhere between about $24 and $649 a month. Some of them print a large milligram figure on the label. None of them comes with a published measurement of how much of that figure reaches you, and one of them contains no NAD⁺ at all.
This page is about what is actually in these products, the two very different technologies sold under one word, and the single human study that has used a NAD⁺ patch — which exists, is rarely mentioned, and does not say what a seller would want it to say. Who sells what, and for how much, is on our NAD⁺ patch board.
Start with the label, because the labels disagree
Read six patch product pages and you get six different relationships with the number that matters.
Two print a precise dose. PatchAid states 600 mg of NAD⁺ and 150 mg of resveratrol per patch and sells thirty of them for $24.95. Push Patch puts 1,300 mg of NAD⁺ in the product name, paired with 5 mg of the copper peptide GHK-Cu — behind a login wall no member of the public can open. Ion Layer states 500 mg per patch and is prescription-only.
Two print nothing. PatchMD’s NAD⁺ page carries no milligram figure anywhere — not in the description, not in the directions, not in a facts panel — and the ingredient its description explains at length is N-acetylcysteine. Gentle Patches states no dose either, at $29.99 for a month.
And one prints a complete, honest ingredient list that dissolves the product. What’s That Patch sells an “NAD+ Longevity” patch whose published formula is NMN 8 mg, resveratrol 5 mg, NAC 5 mg, lion’s mane 5 mg and cordyceps 2 mg. There is no NAD⁺ in it. NMN is a precursor the body converts into NAD⁺, so the name is not baseless — but 8 mg sits far below the doses used in the published oral NMN trials, which run into the hundreds of milligrams.
That spread — 1,300 mg, 600 mg, 500 mg, 8 mg of something else, and two refusals to say — is the first thing to understand about the category. These products are not variations on one dose. They do not share a unit.
Two technologies, one word
Almost every cheap patch is passive: an adhesive pad holding a solution against your skin, relying on the compound to diffuse across by itself. That is the version sold for $25 to $30, without a prescription, alongside magnesium and sleep patches.
A small number are iontophoretic. Iontophoresis uses a small electric current to push charged molecules through skin, and it is a real, established technique built for exactly that class of compound. Ion Layer’s kit is prescription-only, ships NAD⁺ as a powder you reconstitute and load into the patch, and costs $649 for six. AgelessRx sells a loadable weekly patch at $195 a kit; the study discussed below, written by its own staff, describes the patches its patients used as iontophoresis patches.
The distinction matters because the physics objection applies to them very differently. Skin resists molecules much above roughly 500 daltons, an argument built from the observation that essentially every common contact allergen, every standard topical drug and every compound used in a transdermal delivery system sits below that weight [1]. NAD⁺ weighs about 663 daltons and carries two phosphate groups that make it strongly hydrophilic — the wrong profile on both counts. That rule-of-thumb argument is set out in full on our page on topical NAD⁺. A passive patch has no answer to it. An iontophoretic one has a real answer to it, which is the honest reason to treat the two as different products even though they are sold under the same two words.
The human study nobody quotes
Here is the part that is usually got wrong in both directions. It is not true that no human study has ever used a NAD⁺ patch. One has.
A 2024 pilot study enrolled 36 patients with persistent moderate to severe fatigue after COVID-19 and treated them for twelve weeks with low-dose naltrexone at 4.5 mg a day together with NAD⁺ supplementation through iontophoresis patches. Scores improved: mean total SF-36 rose from 36.5 (SD 15.6) to 52.1 (24.8), p < 0.0001, and Chalder fatigue fell from 25.9 (4.6) to 17.4 (9.7), p < 0.0001, with 52% of patients classed as responders. The patches caused mild, short-lived skin irritation in 25% of patients. The authors write that larger randomized controlled trials will have to confirm the data [2].
Now read the design, because it decides what the numbers are worth.
The comparison is against each patient’s own baseline, with no control group reported — and fatigue questionnaires in an open, uncontrolled twelve-week study are about as responsive to expectation as an endpoint can be. Two treatments were given at once, so nothing in the result can be assigned to the patch rather than to the naltrexone. No NAD⁺ measurement appears in the abstract at all: this study reports how people felt, not what was in their blood. And six of its seven authors are employees of AgelessRx — a longevity telehealth service that sells NAD⁺ by injection, nasal spray and patch — which the paper discloses in its own conflict-of-interest statement.
None of that makes the study worthless. A safety signal in 36 patients is worth having, and 25% skin irritation is a real number a buyer should know. It simply cannot carry the claim it would be used to carry.
What we searched, and when
On September 13, 2026 we ran five PubMed queries. The precise claim we were testing is narrow, so the searches are too.
Nicotinamide adenine dinucleotide in the title or abstract combined with transdermal, iontophoresis or skin patch returned eight records: a 2026 nanocarrier paper, a mouse study of NAD⁺ deficiency in skin, a 2023 microneedle formulation study, and five irrelevant hits about breath-imaging cameras and nitric oxide. The same terms restricted to the human MeSH tag returned eight — a partly different set, adding two microneedle engineering papers and a transdermal alcohol-monitoring study. An all-fields search for the phrases “NAD patch”, “NAD+ patch”, “NAD patches” and “NAD+ patches” returned zero. A title search for NAD or NAD+ with patch, patches or transdermal returned three, one of them a mouse genetics paper about a strain called bare patches.
The fifth query is the one that matters, and it is the one that is usually skipped. NAD in the title or abstract combined with iontophoresis returned two records — a 2003 neurophysiology paper, and the COVID fatigue pilot above. A search for “transdermal” never surfaces that study, because the paper says “iontophoresis”. If you want to know whether a format has been tested, search the technology by name as well as the category.
As a known-good control, a search for transdermal patch randomized controlled trials published between 2020 and 2026 returned 99 records the same day, so PubMed was answering normally. The conclusion that survives all of that is precise: no published human study measures NAD⁺ levels after a NAD⁺ patch, by any delivery method, passive or iontophoretic.
The formulation literature is a confession
The most telling reading in this category is not the marketing. It is the work of the scientists trying to make transdermal NAD⁺ happen, who state the problem plainly in their own opening lines.
A 2026 paper developing an ion-coupled NAD⁺ transfersome begins by stating that NAD⁺ delivery to skin is limited by poor stability and tissue accessibility, and reports that its engineered carrier achieves better intratissue penetration in porcine and human skin explants than free NAD⁺ or its precursors [3]. Free NAD⁺ is the thing in a patch. The comparison group in that experiment is the product you can buy. And note what the authors are aiming at: they describe the platform as supporting localized NAD⁺ restoration in skin aging — not systemic repletion, which is what a patch sold as an infusion alternative is claiming.
The microneedle work makes the same point with a number. A 2024 study coated 3D-printed microneedles with NMN, applied them to full-thickness human skin in vitro and measured what came through over 24 hours: about 189 ± 34.5 µg permeated, with 41.2 ± 7.53 µg left in the skin [4]. That is micrograms, from needles that physically pierce the barrier, carrying the smaller precursor molecule rather than NAD⁺ itself. The figures printed on adhesive patches that pierce nothing are three orders of magnitude larger. A coated needle can only hold so much, so this is not a ceiling on what skin can pass — but it is the scale at which careful researchers, using an invasive method, report their results.
So is a $25 patch worth trying anyway?
It is a small amount of money, and that is the honest argument for it. Here is the honest argument against.
For roughly the same monthly outlay you can buy an oral NAD⁺ precursor that states its dose and has randomized human trials behind it. In one randomized, double-blind, placebo-controlled trial, 80 healthy middle-aged adults took placebo or 300, 600 or 900 mg of oral NMN daily for 60 days; blood NAD concentrations rose significantly in every NMN-treated group against both placebo and baseline at day 30 and day 60, at all p ≤ 0.001, and the supplement was well tolerated [5]. That is the comparison that should decide it: between a cheap product whose delivery has been measured and a cheap product whose delivery has not, the measurable one is the better use of the same $25. Which precursors and which doses is on our supplements board.
The wider evidence picture does not rescue the format either. A PRISMA-guided systematic review published in 2026 screened NAD-related intervention studies from January 2010 to October 2025, identified 113 eligible studies including 33 human intervention studies, and found that oral NR and NMN consistently demonstrated biochemical target engagement while effects on healthspan-relevant outcomes were heterogeneous and often null — with no eligible outcomes trial evaluating intravenous or intramuscular NAD⁺ itself [6]. If putting NAD⁺ directly into a vein has no outcomes trial, a sticker is not going to have one.
What to check before you buy one
Read the ingredient list, not the product name. On this format that is not a figure of speech. One patch sold as NAD⁺ contains none.
Find the milligram figure. If there is not one, there is no cost per milligram, no way to compare the patch against a capsule, and no quantity to evaluate even in principle.
Work out whether it is passive or iontophoretic. They are different products at different prices with different plausibility. If the page does not say, assume passive.
Check whether the headline price is the standing price. Struck-through list prices, subscribe-and-save rates and sitewide promotional codes are all common here, and more than one seller’s advertised figure is a markdown rather than the rate that repeats.
Treat a plausible mechanism as a reason to run a trial, not as a result. Iontophoresis genuinely addresses the objection to passive patches. It does not answer it, because nobody has published the measurement — and what NAD⁺ has and has not been shown to do is a separate question again, unsettled in every format.